Drugs / Utomilumab
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT03704298 | Nov 2018 → May 2021 | aggressive B-cell non-Hodgkin lymphoma | Kite, A Gilead Company | Terminated | No outcome recorded |
| Phase 1 | NCT03636503 | Oct 2018 → Jul 2021 | follicular lymphoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03440567 | Jun 2018 → Jun 2024 | diffuse large B-cell lymphoma, mantle cell lymphoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03290937 | Dec 2017 → Dec 2025 | colorectal carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03364348 | Oct 2017 → Feb 2021 | HER2 positive breast carcinoma | George W. Sledge Jr. | Completed | No outcome recorded |
| Phase 1 | NCT02444793 | May 2015 → Sep 2017 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT02315066 | Apr 2015 → Nov 2020 | neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02179918 | Aug 2014 → Feb 2017 | cancer | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01307267 | Jun 2011 → Feb 2019 | diffuse large B-cell lymphoma, follicular lymphoma, head and neck squamous cell carcinoma, melanoma +2 | Pfizer | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03318900 | Sep 2018 → Dec 2023 | ovarian carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03217747 | Aug 2017 → Sep 2025 overdue | castration-resistant prostate carcinoma, metastatic carcinoma in the bone, metastatic prostate carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02554812 | Nov 2015 → Mar 2023 | cancer of unknown primary site | Pfizer | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03971409 | Jul 2019 → Jan 2027 expected | female breast carcinoma, invasive breast carcinoma, triple-negative breast carcinoma | Laura Huppert, MD, BA | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03414658 | Jun 2018 → May 2023 overdue | breast cancer | Adrienne G. Waks | Active not recruiting | Mixed |
| Phase 2 | NCT03258008 | Apr 2018 → Nov 2021 | cancer of unknown primary site, oropharynx squamous cell carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 32 trials | ||||||
| Phase 3 | NCT05059522 | Sep 2021 → Dec 2026 expected | non-small cell lung carcinoma, ovarian cancer, urothelial carcinoma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02951156 | Dec 2016 → Dec 2019 | diffuse large B-cell lymphoma | Pfizer | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-06-04 | Pfizer | Results Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor pfizer.com ↗
Of the 23 patients enrolled in the trial, six had a confirmed complete or partial response. |
All press releases naming this drug 3 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Utomilumab | “Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively.” PMID 36302562 ↗ Oct 202215“A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.” PMID 31801624 ↗ Dec 2019 “Utomilumab (PF-05082566) is an agonistic mAb that engages the immune costimulatory molecule 4-1BB/CD137.” PMID 29549159 ↗ Mar 2018 |
| Known as | PF-05082566 | “Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively.” PMID 36302562 ↗ Oct 20224“* Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)” NCT03414658 ↗ |
| Known as | PF-5082566 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707324 ↗ |
| Action | Activate | “Utomilumab (PF-05082566) is an agonistic mAb that engages the immune costimulatory molecule 4-1BB/CD137.” PMID 29549159 ↗ Mar 20181“Tumor necrosis factor receptor superfamily member 9 agonist” CHEMBL3707324 ↗ |
| Modality | Monoclonal antibody | “a 4-1BB agonist monoclonal antibody (mAb)” NCT01307267 ↗ |
| Route | Intravenous | “Intravenous, Dose escalation, once per month” NCT01307267 ↗ |
| Target | TNFRSF9 | “Tumor necrosis factor receptor superfamily member 9 agonist” CHEMBL3707324 ↗ |